Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Abstract Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously treated advanced squamous (SQ) and non...

Full description

Bibliographic Details
Main Authors: Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
nivolumab
non‐small cell lung cancer (NSCLC)
phase II study
programmed cell death 1 ligand 1 (PD‐L1)
programmed cell death 1 receptor (PD‐1)
Online Access:https://doi.org/10.1002/cam4.2411

Internet

https://doi.org/10.1002/cam4.2411

Similar Items